Corneal Transplantation and Immune Privilege

REFERENCES

• Bigger SL. An inquiry into the possibility of transplanting the cornea with the view of relieving blindness (hitherto deemed incurable) caused by several diseases of that structure. Dublin J Med Sci 1837;11:408–447.
   Google Scholar
• Kissam R. Ceratoplastice in man. New York J Med 1844;2:281–289.
   Google Scholar
• Zirm E. Eine erfolgreiche totale Keratoplastik. Graefes Arch Ophthalmol 1906;64:580–593.
   Google Scholar
• EBAA. Statistical report on eye banking activity for 2008. Available from: http://www.restoresight. org/about-us/understanding-donation/cornea-donation-transplantation-statistics/.
   Google Scholar
• Billingham RE, Boswell T. Studies on the problem of corneal homografts. Proc R Soc Lond B Biol Sci 1953;141(904):392–406.
   PubMedGoogle Scholar
• Medawar PB. Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 1948;29:58–69.
   PubMed Web of Science ®Google Scholar
• Waldock A, Cook SD. Corneal transplantation: how successful are we? Br J Ophthalmol 2000;84(8):813–815.
   PubMed Web of Science ®Google Scholar
• Niederkorn JY. The immune privilege of corneal grafts. J Leukoc Biol 2003;74(2):167–171. Epub 2003/07/30.
   PubMedGoogle Scholar
• Sonoda Y, Streilein JW. Orthotopic corneal transplantation in mice–evidence that the immunogenetic rules of rejection do not apply. Transplantation 1992;54(4):694–704.
   PubMedGoogle Scholar
• Ross J, He YG, Niederkorn JY. Class I disparate corneal grafts enjoy afferent but not efferent blockade of the immune response. Curr Eye Res 1991;10(9):889–892.
   PubMed Web of Science ®Google Scholar
• Ross J, Callanan D, Kunz H, Niederkorn J. Evidence that the fate of class II-disparate corneal grafts is determined by the timing of class II expression. Transplantation 1991;51(2):532–536.
   PubMedGoogle Scholar
• He YG, Niederkorn JY. Depletion of donor-derived Langerhans cells promotes corneal allograft survival. Cornea 1996;15(1):82–89.
   PubMedGoogle Scholar
• Streilein JW. New thoughts on the immunology of corneal transplantation. Eye 2003;17(8):943–948.
   PubMed Web of Science ®Google Scholar
• Yamada J, Yoshida M, Taylor AW, Streilein JW. Mice with Th2-biased immune systems accept orthotopic corneal allografts placed in “high risk” eyes. J Immunol 1999;162(9):5247–5255.
   PubMedGoogle Scholar
• Smolin G, Hyndiuk RA. Lymphatic drainage from vascularized rabbit cornea. Am J Ophthalmol 1971;72(1):147–151.
   PubMedGoogle Scholar
• Yamagami S, Dana MR. The critical role of lymph nodes in corneal alloimmunization and graft rejection. Invest Ophthalmol Vis Sci 2001;42(6):1293–1298.
   PubMedGoogle Scholar
• Dietrich T, Bock F, Yuen D, Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol 2010;184(2):535–539. Epub 2009/12/19.
   PubMedGoogle Scholar
• Cursiefen C, Chen L, Saint-Geniez M, Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A 2006;103(30):11405–11410. Epub 2006/07/20.
   PubMed Web of Science ®Google Scholar
• Albuquerque RJ, Hayashi T, Cho WG, Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 2009;15(9):1023–1030. Epub 2009/08/12.
   PubMed Web of Science ®Google Scholar
• Brideau G, Makinen MJ, Elamaa H, Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res 2007;67(24):11528–11535. Epub 2007/12/20.
   PubMedGoogle Scholar
• Tan Y, Cruz-Guilloty F, Medina-Mendez CA, Immunological disruption of antiangiogenic signals by recruited allospecific T cells leads to corneal allograft rejection. J Immunol 2012;188(12):5962–5969. Epub 2012/05/18.
   PubMedGoogle Scholar
• Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol 2006;7(4):354–359.
   PubMed Web of Science ®Google Scholar
• Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003;3(11):879–889.
   PubMed Web of Science ®Google Scholar
• Wilbanks GA, Streilein JW. Distinctive humoral immune responses following anterior chamber and intravenous administration of soluble antigen. Evidence for active suppression of IgG2-secreting B lymphocytes. Immunology 1990;71(4):566–572.
   PubMedGoogle Scholar
• Niederkorn JY. Anterior chamber-associated immune deviation and its impact on corneal allograft survival. Current Opinion in Organ Transplant 2006;11:360–365.
   Google Scholar
• Niederkorn JY, Mellon J. Anterior chamber-associated immune deviation promotes corneal allograft survival. Invest Ophthalmol Vis Sci 1996;37(13):2700–2707.
   PubMedGoogle Scholar
• Streilein JW, Niederkorn JY. Induction of anterior chamber-associated immune deviation requires an intact, functional spleen. J Exp Med 1981;153(5):1058–1067.
   PubMed Web of Science ®Google Scholar
• Sonoda Y, Streilein JW. Impaired cell-mediated immunity in mice bearing healthy orthotopic corneal allografts. J Immunol 1993;150(5):1727–1734.
   PubMedGoogle Scholar
• Skelsey ME, Mellon J, Niederkorn JY. Gamma delta T cells are needed for ocular immune privilege and corneal graft survival. J Immunol 2001;166(7):4327–4333.
   PubMedGoogle Scholar
• Sonoda KH, Taniguchi M, Stein-Streilein J. Long-term survival of corneal allografts is dependent on intact CD1d- reactive NKT cells. J Immunol 2002;168(4):2028–2034.
   PubMedGoogle Scholar
• Niederkorn JY, Mellon J. Anterior chamber-associated immune deviation promotes corneal allograft survival. Invest Ophthalmol Vis Sci 1996;37(13):2700–2707. Epub 1996/12/01.
   PubMedGoogle Scholar
• She SC, Moticka EJ. Ability of intracamerally inoculated B- and T-cell enriched allogeneic lymphocytes to enhance corneal allograft survival. Int Ophthalmol 1993;17(1):1–7.
   PubMedGoogle Scholar
• She SC, Steahly LP, Moticka EJ. Intracameral injection of allogeneic lymphocytes enhances corneal graft survival. Invest Ophthalmol Vis Sci 1990;31(10):1950–1956.
   PubMedGoogle Scholar
• Cunnusamy K, Paunicka K, Reyes N, Two different regulatory T cell populations that promote corneal allograft survival. Invest Ophthalmol Vis Sci 2010;51(12):6566–6574. Epub 2010/08/13.
   PubMed Web of Science ®Google Scholar
• Hori J, Taniguchi H, Wang M, GITR ligand-mediated local expansion of regulatory T cells and immune privilege of corneal allografts. Invest Ophthalmol Vis Sci 2010;51(12):6556–6565. Epub 2010/08/13.
   PubMedGoogle Scholar
• Cunnusamy K, Chen PW, Niederkorn JY. IL-17 promotes immune privilege of corneal allografts. J Immunol 2010;185(8):4651–4658. Epub 2010/09/17.
   PubMedGoogle Scholar
• Cunnusamy K, Chen PW, Niederkorn JY. IL-17A-dependent CD4+CD25+ regulatory T cells promote immune privilege of corneal allografts. J Immunol 2011;186(12):6737–6745. Epub 2011/05/10.
   PubMedGoogle Scholar
• Chauhan SK, Saban DR, Lee HK, Dana R. Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. J Immunol 2009;182(1):148–153. Epub 2008/12/26.
   PubMed Web of Science ®Google Scholar
• Griffith TS, Brunner T, Fletcher SM, Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270(5239):1189–1192.
   PubMed Web of Science ®Google Scholar
• Stuart PM, Griffith TS, Usui N, CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997;99(3):396–402.
   PubMedGoogle Scholar
• Yamagami S, Kawashima H, Tsuru T, Role of Fas-Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation 1997;64(8):1107–1111.
   PubMedGoogle Scholar
• Hori J, Wang M, Miyashita M, B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol 2006;177(9):5928–5935.
   PubMed Web of Science ®Google Scholar
• Shen L, Jin Y, Freeman GJ, The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival. J Immunol 2007;179(6):3672–3679.
   PubMed Web of Science ®Google Scholar
• Lee HO, Herndon JM, Barreiro R, TRAIL: a mechanism of tumor surveillance in an immune privileged site. J Immunol 2002;169(9):4739–4744.
   PubMedGoogle Scholar
• Wang S, Boonman ZF, Li HC, Role of TRAIL and IFN-gamma in CD4+ T cell-dependent tumor rejection in the anterior chamber of the eye. J Immunol 2003;171(6):2789–2796.
   PubMedGoogle Scholar
• Hegde S, Mellon JK, Hargrave SL, Niederkorn JY. Effect of alloantibodies on corneal allograft survival. Invest Ophthalmol Vis Sci 2002;43(4):1012–1018.
   PubMedGoogle Scholar
• Holan V, Vitova A, Krulova M, Susceptibility of corneal allografts and xenografts to antibody-mediated rejection. Immunol Lett 2005;100(2):211–213.
   PubMedGoogle Scholar
• Hegde S, Beauregard C, Mayhew E, Niederkorn JY. CD4(+) T-cell-mediated mechanisms of corneal allograft rejection: role of Fas-induced apoptosis. Transplantation 2005;79(1):23–31.
   PubMed Web of Science ®Google Scholar
• Niederkorn JY, Stevens C, Mellon J, Mayhew E. CD4+ T-cell-independent rejection of corneal allografts. Transplantation 2006;81(8):1171–1178.
   PubMed Web of Science ®Google Scholar
• Niederkorn JY, Stevens C, Mellon J, Mayhew E. Differential roles of CD8+ and CD8− T lymphocytes in corneal allograft rejection in ‘high-risk’ hosts. Am J Transplant 2006;6(4):705–713.
   PubMedGoogle Scholar
• Bora NS, Gobleman CL, Atkinson JP, Differential expression of the complement regulatory proteins in the human eye. Invest Ophthalmol Vis Sci 1993;34(13):3579–3584.
   PubMedGoogle Scholar
• Goslings WR, Prodeus AP, Streilein JW, A small molecular weight factor in aqueous humor acts on C1q to prevent antibody-dependent complement activation. Invest Ophthalmol Vis Sci 1998;39(6):989–995.
   PubMedGoogle Scholar
• Lass JH, Walter EI, Burris TE, Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland. Invest Ophthalmol Vis Sci 1990;31(6):1136–1148.
   PubMedGoogle Scholar
• Hargrave SL, Mayhew E, Hegde S, Niederkorn J. Are corneal cells susceptible to antibody-mediated killing in corneal allograft rejection? Transpl Immunol 2003;11(1):79–89.
   PubMedGoogle Scholar
• Esposito A, Suedekum B, Liu J, Decay accelerating factor is essential for successful corneal engraftment. Am J Transplant: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2010;10(3):527–534. Epub 2010/01/09.
   PubMedGoogle Scholar
• Liu J, Lin F, Strainic MG, IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production. J Immunol 2008;180(9):5882–5889. Epub 2008/04/22.
   PubMedGoogle Scholar
• Strainic MG, Liu J, Huang D, Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 2008;28(3):425–435. Epub 2008/03/11.
   PubMed Web of Science ®Google Scholar
• Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today 1990;11(7):237–244.
   PubMedGoogle Scholar
• Claerhout I, Kestelyn P, Debacker V, et al. Role of natural killer cells in the rejection process of corneal allografts in rats. Transplantation 2004;77(5):676–682.
   PubMedGoogle Scholar
• Apte RS, Mayhew E, Niederkorn JY. Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors. Invest Ophthalmol Vis Sci 1997;38(6):1277–1282.
   PubMed Web of Science ®Google Scholar
• Apte RS, Niederkorn JY. Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. J Immunol 1996;156(8):2667–2673.
   PubMed Web of Science ®Google Scholar
• Apte RS, Sinha D, Mayhew E, Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol 1998;160(12):5693–5696.
   PubMed Web of Science ®Google Scholar
• Rook AH, Kehrl JH, Wakefield LM, Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986;136(10):3916–3920.
   PubMed Web of Science ®Google Scholar
• Streilein JW. Immune regulation and the eye: a dangerous compromise. FASEB J 1987;1(3):199–208.
   PubMed Web of Science ®Google Scholar
• Niederkorn JY, Stein-Streilein J. History and physiology of immune privilege. Ocul Immunol Inflamm 2010;18(1):19–23. Epub 2010/02/05.
   PubMed Web of Science ®Google Scholar
• Metcalf JF, Hamilton DS, Reichert RW. Herpetic keratitis in athymic (nude) mice. Infect Immun 1979;26(3):1164–1171.
   PubMedGoogle Scholar
• He YG, Ross J, Niederkorn JY. Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody. Invest Ophthalmol Vis Sci 1991;32(10):2723–2728.
   PubMedGoogle Scholar
• Ayliffe W, Alam Y, Bell EB, Prolongation of rat corneal graft survival by treatment with anti-CD4 monoclonal antibody. Br J Ophthalmol 1992;76(10):602–606.
   PubMedGoogle Scholar
• Yamada J, Kurimoto I, Streilein JW. Role of CD4+ T cells in immunobiology of orthotopic corneal transplants in mice. Invest Ophthalmol Vis Sci 1999;40(11):2614–2621.
   PubMedGoogle Scholar
• Nickerson P, Steurer W, Steiger J, Cytokines and the Th1/Th2 paradigm in transplantation. Curr Opin Immunol 1994;6(5):757–764.
   PubMedGoogle Scholar
• Beauregard C, Stevens C, Mayhew E, Niederkorn JY. Cutting edge: atopy promotes Th2 responses to alloantigens and increases the incidence and tempo of corneal allograft rejection. J Immunol 2005;174(11):6577–6581.
   PubMedGoogle Scholar
• Hargrave SL, Hay C, Mellon J, Fate of MHC-matched corneal allografts in Th1-deficient hosts. Invest Ophthalmol Vis Sci 2004;45:1188–1193.
   PubMed Web of Science ®Google Scholar
• Niederkorn JY, Chen PW, Mellon J, Allergic airway hyperreactivity increases the risk for corneal allograft rejection. Am J Transplant: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2009;9(5):1017–1026. Epub 2009/05/09.
   PubMedGoogle Scholar
• Niederkorn JY, Chen PW, Mellon J, Allergic conjunctivitis exacerbates corneal allograft rejection by activating Th1 and th2 alloimmune responses. J Immunol 2010;184(11):6076–6083. Epub 2010/04/23.
   PubMed Web of Science ®Google Scholar
• Cua DJ, Sherlock J, Chen Y, Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003;421(6924):744–748. Epub 2003/03/01.
   PubMed Web of Science ®Google Scholar
• De Paiva CS, Chotikavanich S, Pangelinan SB, IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol 2009;2(3):243–253. Epub 2009/02/27.
   PubMed Web of Science ®Google Scholar
• Hirota K, Hashimoto M, Yoshitomi H, T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med 2007;204(1):41–47. Epub 2007/01/18.
   PubMed Web of Science ®Google Scholar
• Luger D, Silver PB, Tang J, Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 2008;205(4):799–810.
   PubMed Web of Science ®Google Scholar
• Chen H, Wang W, Xie H, A pathogenic role of IL-17 at the early stage of corneal allograft rejection. Transpl Immunol 2009;21(3):155–161. Epub 2009/04/11.
   PubMedGoogle Scholar
• Yamada J, Hamuro J, Fukushima A, MHC-matched corneal allograft rejection in an IFN-gamma/IL-17-independent manner in C57BL/6 mice. Invest Ophthalmol Vis Sci 2009;50(5):2139–2146. Epub 2009/01/13.
   PubMedGoogle Scholar
• Ke Y, Liu K, Huang GQ, Anti-inflammatory role of IL-17 in experimental autoimmune uveitis. J Immunol 2009;182(5):3183–3190. Epub 2009/02/24.
   PubMed Web of Science ®Google Scholar
• Restifo NP. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 2000;6(5):493–495.
   PubMedGoogle Scholar
• Cone RE, Li X, Sharafieh R, Intracameral antigen induces Qa-1-restricted splenic regulatory (suppressor) T cells that require interferon-gamma to induce immunosuppression. ARVO abstract #5152 (page 240). Rockville, MD: Association for Research in Vision and Ophthalmology; 2006.
   Google Scholar
• Cone RE, Li X, Sharafieh R, The suppression of delayed-type hypersensitivity by CD8+ regulatory T cells requires interferon-gamma. Immunology 2007;120(1):112–119.
   PubMedGoogle Scholar
• Paunicka K, Chen PW, Niederkorn JY. Role of IFN-gamma in the establishment of anterior chamber-associated immune deviation (ACAID)-induced CD8+ T regulatory cells. J Leukoc Biol 2012;91(3):475–483. Epub 2011/12/20.
   PubMedGoogle Scholar